FDMT

10.1705.13%
JF

John F. Milligan

Independent Chairman

Dr. John F. Milligan, Ph.D., serves as Independent Non-Employee Chair at Kailera Therapeutics, Inc. and is Independent Non-Employee Director since September 2024. He is Chairman of the Board of Aiolos Bio, Inc. from October 2023. He has been an Independent Chairman of the Board at Pacific Biosciences of California, Inc. since September 14, 2020. Dr. Milligan has been Executive Chairman of 4D Molecular Therapeutics, Inc. since August 2020. He has been the President of Pharmasset, Inc. since January 17, 2012. Dr. Milligan serves as a Director at TurnCare, Inc., since January 2024. Dr. Milligan has served as executive chair of the board of directors of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) since August 2020 and as a director of PacBio, Inc. since July 2014 and chair of the board since September 2020. Dr. Milligan served as the Chief Executive Officer at Gilead Sciences, Inc. since March 10, 2016 until December 31, 2018 and served as its President since May 2008 until February 2019. He was appointed as the Chief Operating Officer at Gilead Sciences, Inc. from March 09, 2007 to March 10, 2016. Dr. Milligan serves as the Chief Financial Officer of Gilead Sciences, Inc. since March 2002 and its Executive Vice President since July 2003, Principal Accounting Officer until May 2008 and Senior Vice President from March 2002 to July 2003. He joined Gilead Sciences in 1990 as a Research Scientist. He was the President of Gilead Sciences and Chief Operating Officer of Gilead Sciences at Gilead Palo Alto, Inc. Since 1996, he was made Director of Project Management and Project Team Leader for Gilead and Hoffmann-La Roche collaboration on Tamiflu®. In 1998, he transitioned to Corporate Development of Gilead and since March 2000, he served as its Vice President Corporate Development with responsibility for licensing, corporate partnerships and mergers and acquisitions. He was named Bay Area Chief Financial Officer of the Year in 2006 for companies. He served as Director of Gilead Sciences, Inc. since January 2016 until December 31, 2018. He has been a Director of Gilead Pharmasset LLC (Formerly known as Pharmasset, Inc.) since January 17, 2012. He has been an Independent of Pacific Biosciences of California, Inc. since July 18, 2013. He was named the top biotechnology industry Chief Financial Officer in the United States by Institutional Investor magazine in 2007 and 2006. He was an American Cancer Society Postdoctoral Fellow at the University of California at San Francisco Medical Center. Dr. Milligan is a Chair of the board of Trustee of Ohio Wesleyan University. Dr. Milligan received B.A. in Chemistry from Ohio Wesleyan University in 1983 and his Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign in 1988.

Positions